Journal of Investigative Medicine High Impact Case Reports (Aug 2016)

Ipilimumab-Induced Neutropenia in Melanoma

  • Makiko Ban-Hoefen MD,
  • Richard Burack MD,
  • Lynn Sievert NP,
  • Deepak Sahasrabudhe MD

DOI
https://doi.org/10.1177/2324709616661835
Journal volume & issue
Vol. 4

Abstract

Read online

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.